Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C. (CIATEJ), 44270 Guadalajara, Mexico.
Centro de Investigación Biomédica de Occidente (CIBO), División de Inmunología, Instituto Mexicano del Seguro Social (IMSS), 44340 Guadalajara, Mexico.
Biosensors (Basel). 2020 Oct 21;10(10):149. doi: 10.3390/bios10100149.
Several studies have shown that patients with cancer have antibodies in serum that react with cellular autoantigens, known as Tumor-Associated Antigens (TAA). The present work aimed to determine whether a mini-array comprising four recombinant TAA increases the detection of specific serum antibodies for the diagnosis of early-stage breast cancer. The mini-array included Alpha 1-AntiTrypsin (A1AT), TriosePhosphate Isomerase 1 (TPI1), Peptidyl-Prolyl cis-trans Isomerase A (PPIA), and PeroxiReDoXin 2 (PRDX2) full-length recombinant proteins. The proteins were produced after gene cloning, expression, and purification, and were verified by Western blot assays. Then, Dot-Blot was performed to find antibodies against the four TAA in 12 sera from women with early-stage breast cancer (stage II) and 12 sera from healthy women. Antibody detection against individual TAA in early-stage breast cancer sera ranged from 58.3% to 83.3%. However, evaluation of the four TAA showed that there was a positive antibody reaction reaching a sensitivity of 100% and a specificity of 85% in early-stage breast cancer, suggesting that this mini-array must be evaluated as a clinical diagnostic tool for early-stage breast cancer in a larger sample size. Our results suggest that TAA mini-arrays may provide a promising and powerful method for improving the detection of breast cancer in Mexican women.
几项研究表明，癌症患者的血清中有与细胞自身抗原反应的抗体，这些自身抗原被称为肿瘤相关抗原（TAA）。本研究旨在确定由四个重组 TAA 组成的 mini-array 是否可以提高对早期乳腺癌的特异性血清抗体的检测。mini-array 包括全长重组蛋白 Alpha 1-AntiTrypsin (A1AT)、TriosePhosphate Isomerase 1 (TPI1)、Peptidyl-Prolyl cis-trans Isomerase A (PPIA) 和 PeroxiReDoXin 2 (PRDX2)。这些蛋白通过基因克隆、表达和纯化生产，并通过 Western blot 分析进行验证。然后，通过 Dot-Blot 分析在 12 例早期乳腺癌（II 期）患者血清和 12 例健康女性血清中寻找针对这四个 TAA 的抗体。针对早期乳腺癌患者血清中单个 TAA 的抗体检测率在 58.3%至 83.3%之间。然而，对四个 TAA 的评估表明，在早期乳腺癌中，该 mini-array 显示出阳性抗体反应，灵敏度为 100%，特异性为 85%，提示该 mini-array 必须在更大的样本量中评估为早期乳腺癌的临床诊断工具。我们的结果表明，TAA mini-array 可能为提高墨西哥女性乳腺癌的检测提供一种有前途和强大的方法。
